Zacks Investment Research on MSN
DexCom (DXCM) reports next week: Wall Street expects earnings growth
Wall Street expects a year-over-year increase in earnings on higher revenues when DexCom (DXCM) reports results for the ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and ...
SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...
Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled ...
Investor's Business Daily on MSN
Could 2026 be Dexcom's 'get right' year? New CEO Jake Leach says yes.
For the first time in a decade, Dexcom has a new chief executive. And, to say Jake Leach has his work cut out for him is ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...
Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc (DXCM). (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program ...
DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this ...
DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results